This mini case study review article is the third in a series exploring tumour necrosis factor (TNF) inhibitors in the treatment of immune-mediated disease. This article explores anti-TNF therapies, which are generally considered to be an effective, well-tolerated treatment option for the management of chronic conditions related to the overproduction of TNF-α.
EMJ Gastroenterology 11 [Supplement 7] . 2022
November 2022
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given